News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Summit Therapeutics: Result Of AGM



7/18/2017 10:31:54 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

Summit Therapeutics plc

('Summit' or 'the Company')

RESULT OF ANNUAL GENERAL MEETING

Oxford, UK, 18 July 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that all resolutions proposed to shareholders at the Company's Annual General Meeting ('AGM') held earlier today were duly passed. The results of the proxy votes lodged in advance and at the meeting will be available shortly from the Investors section of Summit's website, www.summitplc.com.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit
Glyn Edwards / Richard Pye (UK office)

Erik Ostrowski / Michelle Avery (US office)



Tel: +44 (0)1235 443 951

+1 617 225 4455
Cairn Financial Advisers LLP

(Nominated Adviser)

Liam Murray / Tony Rawlinson





Tel: +44 (0)20 7213 0880
N+1 Singer

(Broker)

Aubrey Powell / Lauren Kettle





Tel: +44 (0)20 7496 3000
MacDougall Biomedical Communications

(US media contact)

Karen Sharma

Tel: +1 781 235 3060

ksharma@macbiocom.com

Consilium Strategic Communications
(Financial public relations, UK)

Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Lindsey Neville
Tel: +44 (0)20 3709 5700

summit@consilium-comms.com

-END-


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES